Literature DB >> 3538741

Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans.

G A Spinas, T Mandrup-Poulsen, J Mølvig, L Baek, K Bendtzen, C A Dinarello, J Nerup.   

Abstract

Isolated rat islets were incubated either with crude, affinity-purified or recombinant human interleukin-1 for 1 to 6 days. A significant (20-60%) increase of insulin release was observed at low concentrations of all three interleukin-1-containing preparations. In contrast, higher concentrations dose-dependently inhibited the insulin release. The increased insulin secretion occurred at concentrations below those necessary to augment the mitogen response to phytohaemagglutinin of murine thymocytes in vitro. These doses (0.05-0.5 U/ml) correspond to 0.2-2 ng of recombinant interleukin-1 per ml, equal to approximately 0.01-0.1 pmol/ml. In doses of 0.6-1.8 U/ml affinity-purified interleukin-1 significantly increased the islet insulin content per ng of DNA, indicating a stimulation of insulin-biosynthesis. The data support the concept that low concentrations of interleukin-1 may play a role in priming the physiological secretion of insulin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3538741     DOI: 10.1530/acta.0.1130551

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  35 in total

Review 1.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

2.  Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines.

Authors:  M Lundh; D P Christensen; D N Rasmussen; P Mascagni; C A Dinarello; N Billestrup; L G Grunnet; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2010-09-28       Impact factor: 10.122

3.  Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1.

Authors:  C Southern; D Schulster; I C Green
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

4.  Involvement of interleukin-1 in the inhibition of in vivo insulin release: possible role of adrenal glands.

Authors:  H Shimizu; Y Uehara; Y Shimomura; M Negishi; I Kobayashi; S Kobayashi
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

Review 5.  Extracellular Vesicles in Type 1 Diabetes: Messengers and Regulators.

Authors:  Sarita Negi; Alissa K Rutman; Steven Paraskevas
Journal:  Curr Diab Rep       Date:  2019-07-31       Impact factor: 4.810

Review 6.  The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes.

Authors:  James W Ramadan; Stephen R Steiner; Christina M O'Neill; Craig S Nunemaker
Journal:  Cell Calcium       Date:  2011-09-23       Impact factor: 6.817

7.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

8.  Secretory Functions of Macrophages in the Human Pancreatic Islet Are Regulated by Endogenous Purinergic Signaling.

Authors:  Jonathan R Weitz; Carol Jacques-Silva; Mirza Muhammed Fahd Qadir; Oliver Umland; Elizabeth Pereira; Farhan Qureshi; Alejandro Tamayo; Juan Dominguez-Bendala; Rayner Rodriguez-Diaz; Joana Almaça; Alejandro Caicedo
Journal:  Diabetes       Date:  2020-04-03       Impact factor: 9.461

9.  Antidiabetic effects of interleukin 1.

Authors:  A del Rey; H Besedovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  Hypoglycemia, hormones and cytokines in fatal meningococcal septicemia.

Authors:  J A Romijn; M H Godfried; C Wortel; H P Sauerwein
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.